Experimental studies on reproduction with the lipid-regulating agent XXXX .

@entity35 @entity137 @entity95 @entity8445
@entity8445 , a new lipid-regulating agent, was evaluated in @entity35 and @entity95 for effects on various phases of the reproduction process. In teratology studies groups of pregnant @entity35 and @entity95 received @entity8445 at doses up to 200 mg/kg during organogenesis ( @entity35 , Days 6-15; @entity95 , days 6-18). For peri- and postnatal studies, groups of pregnant @entity35 were given 92 or 331 mg/kg from Day 15 of gestation through weaning. In fertility studies groups of sexually mature male @entity35 were given 93 or 326 mg/kg of @entity8445 for 61 days and females were given 94 or 318 mg/kg for 15 days prior to mating within treatment groups. Drug administration continued in females through gestation and weaning of the F1 offspring. In subsequent fertility experiments, treated male @entity35 were mated with untreated females and treated females were cohabitated with untreated males. @entity8445 did not elicit a teratogenic response in either @entity35 or @entity95 up to doses that resulted in maternal @entity137 . Reduced pup weights during the neonatal and weaning periods in the female fertility study as well as in the perinatal-postnatal study were the only apparent drug effect. Treatment of female @entity35 prior to mating had no significant effects on general reproductive parameters. Male @entity35 given doses of about 300 mg/kg/day showed inconsistent and equivocal lower rates of fertility relative to the concurrent controls. No adverse effects were seen in the reproductive performance of offspring of @entity8445 -treated male @entity35 .
